Back to Clinical Trials
Phase 1Recruiting

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Sponsored by Pfizer

About this study

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.

Where this study is enrolling (3)

  • The University of Texas, MD Anderson Cancer Center - Sugar Land

    Sugar Land, Texas

    Call 281-566-1900

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • The University of Texas, MD Anderson Cancer Center - West Houston

    Houston, Texas

    Call 713-563-9600

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

    Call 877-632-6789

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

Who can participate

Inclusion criteria

  • ✓18 years of age or older
  • ✓Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas
  • ✓Measurable disease
  • ✓ECOG Performance status 0-1
  • ✓Part 1: progression or relapse following standard treatments
  • ✓Part 2: maximum of 2 prior lines of systemic therapy in the advanced setting
  • ✓Resolution of acute effects of prior anticancer therapy to baseline or Grade 1
  • ✓Consent to submit required pre-treatment tumor tissue as medically feasible

Exclusion criteria

  • ✕Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan )
  • ✕Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion
  • ✕Pulmonary disease meeting protocol exclusion
  • ✕Other unacceptable abnormalities as defined by protocol

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.